Mounjaro vs Ozempic for Weight Loss UK

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both injectable medications that have transformed the treatment of obesity in the UK over the past several years. Although both are used extensively for weight loss, it is important to understand their licensing backgrounds.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is licensed in the UK for the management of type 2 diabetes in adults, not primarily for obesity. The weight loss version of semaglutide is Wegovy (semaglutide 2.4 mg), which carries a specific obesity licence. Ozempic is nonetheless commonly prescribed off-label for weight management in private clinics.

Mounjaro (tirzepatide) is licensed in the UK for both type 2 diabetes and, since late 2023, for chronic weight management in adults with a BMI of 30 kg/m² or above (or 27 kg/m² with at least one weight-related comorbidity). This makes it one of the most broadly licensed weight loss medications currently available in the UK.

Both medications are administered as weekly subcutaneous injections via pre-filled auto-injector pens. They work through distinct but overlapping mechanisms — a critical difference when comparing their efficacy.

The headline efficacy comparison comes from two major clinical trial programmes:

STEP trials (semaglutide / Wegovy): - STEP 1 (participants without diabetes): average weight reduction of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg - STEP 4 (sustained weight loss): participants who continued semaglutide maintained weight loss; those switched to placebo regained most weight - Benchmark result: roughly 1 in 3 participants lost more than 20% of body weight

SURMOUNT trials (tirzepatide / Mounjaro): - SURMOUNT-1 (participants without diabetes): average weight reduction of 20.9% at the highest dose (15 mg) over 72 weeks - At the 10 mg dose: average reduction of 19.5% - At the 5 mg dose: average reduction of 15.0% - Approximately 1 in 3 participants on the 15 mg dose lost more than 25% of body weight

Key interpretation: Tirzepatide consistently outperformed semaglutide on average weight reduction in head-to-head analyses, partly because tirzepatide acts as a dual GIP/GLP-1 agonist whereas semaglutide is a selective GLP-1 agonist. The additional GIP receptor activity appears to confer meaningfully greater efficacy at the population level, though individual responses vary considerably.

It is worth noting that these trials used different comparator doses and timelines, so direct comparison has limitations. Both medications show substantially greater efficacy than older anti-obesity agents.

NHS availability:

Wegovy (semaglutide 2.4 mg) is available on the NHS through specialist weight management services (Tier 3) in England, with NICE guidance TA875 recommending it for adults with BMI ≥35 plus at least one comorbidity, or BMI ≥30–34.9 with specific criteria. Rollout has been phased and waiting lists remain substantial.

Mounjaro is approved by NICE (TA1026) for NHS use in weight management but deployment remains within specialist services; as of early 2026, NHS access outside trial sites and early access schemes is limited.

Private market costs (approximate, April 2026): - Ozempic (0.5–2 mg, off-label for weight loss): £80–£160 per month depending on dose and pharmacy - Wegovy (2.4 mg, for weight loss): £180–£250 per month at maintenance dose - Mounjaro (2.5–15 mg): £150–£290 per month depending on dose

Private telehealth platforms often bundle prescriber consultations into a monthly subscription, adding £30–£60/month. Total treatment costs for Mounjaro or Wegovy in the private market typically run £200–£320/month once all fees are included.

Supply constraints for Wegovy have periodically affected UK availability; Mounjaro supply has been more stable through 2025–26.

Both medications share a broadly similar gastrointestinal side effect profile, reflecting their shared GLP-1 mechanism:

Most common side effects (both drugs): - Nausea (most common, particularly during dose titration) - Vomiting - Diarrhoea or constipation - Abdominal pain or discomfort - Reduced appetite (this is also part of the intended effect) - Fatigue

Mounjaro-specific considerations: - As a dual agonist, Mounjaro may cause more pronounced nausea during titration in some patients — though clinical trial discontinuation rates were similar to semaglutide - Hair thinning (telogen effluvium) has been reported with tirzepatide, likely related to rapid weight loss rather than the drug itself

Serious but rare risks (both): - Pancreatitis — seek immediate medical attention if severe abdominal pain develops; stop medication and do not restart without specialist review - Medullary thyroid carcinoma — both drugs carry a theoretical risk based on rodent data; contraindicated in patients with personal or family history of MTC or MEN2 syndrome - Diabetic retinopathy complications — relevant primarily in patients with pre-existing retinopathy

The overall tolerability profiles are comparable. Most side effects are dose-dependent and often improve after the initial weeks of treatment.

*This article is for informational purposes only. Always consult a qualified UK prescriber before starting any weight loss medication.*

The decision between Mounjaro and Ozempic/Wegovy is one to make with your prescriber, informed by your individual health profile. That said, here are the practical considerations:

Arguments for Mounjaro (tirzepatide): - Stronger average weight loss in clinical trials (approximately 5 percentage points greater at comparable doses) - Licensed specifically for weight management in the UK — cleaner prescribing pathway in private settings - May be preferable for patients who have tried semaglutide without achieving adequate response

Arguments for Ozempic/Wegovy (semaglutide): - Longer real-world safety data (semaglutide has been in widespread use since 2018) - Wegovy has the most robust NHS pathway for obesity — relevant if you are pursuing NHS access - Some patients tolerate semaglutide better than tirzepatide despite the average efficacy difference - Ozempic is sometimes more readily available or lower cost in the private market

Practical questions to discuss with your prescriber: - Do you have type 2 diabetes? (Affects licenced indication and prescribing pathway) - Have you tried a GLP-1 agonist before without adequate response? - What is your target weight loss and timeline? - Are you at risk for any specific contraindications?

Ultimately, both medications represent a significant advance in UK weight management pharmacotherapy. For many patients in the private sector, Mounjaro is now the first-line choice based on its efficacy profile — but semaglutide remains a highly effective option, particularly for NHS-pathway patients.